My­ovan­t's re­l­u­golix clears first uter­ine fi­broids PhI­II test, but com­pe­ti­tion from Ab­b­Vie/Neu­ro­crine makes in­vestors jit­tery

Vivek Ra­maswamy’s bet on Take­da’s re­l­u­golix has worked — sort of.

Less than three years af­ter the pro­lif­ic deal­mak­er spawned My­ovant as part of his um­brel­la of ‘Vants’ with a record $218 mil­lion IPO, the treat­ment in-li­censed from the Japan­ese drug­mak­er passed muster in a late-stage study in women with uter­ine fi­broids, which are com­mon non-can­cer­ous fe­male re­pro­duc­tive tract tu­mors. But in­vestors were not quite as im­pressed as the com­pa­ny’s shares $MY­OV tum­bled in ear­ly Tues­day trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER